Assessment Of Lipid Profile In Cirrhotic Patients

Cirrhosis Clinical Trial

Official title:

Assessment Of Lipid Profile In Cirrhotic Patients And Its Relation To The Disease Severity.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04788173
• Other study ID #: Soh-Med-21-02-15
• Status: Completed
• Start date: March 1, 2021
• Est. completion date: September 1, 2021

Study information

• Verified date: February 2021
• Source: Sohag University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Cirrhosis is defined anatomically as a diffuse process with fibrosis and nodule formation. It is the result of the fibrogenesis that occurs with chronic liver injury.

Lipoproteins are complexes of lipid and proteins that are essential for transport of soluble vitamins Liver cells play a serious task in the regulation of lipid metabolism. The principal location for lipoprotein and cholesterol synthesis is in the liver.

In healthy individuals, a compound equilibrium is preserved between utilization, biosynthesis, and transfer of lipid fractions.

Many diseases that affect the parenchyma can lead to changes in the structure of lipoproteins and transport throughout the blood.

Nevertheless, in cirrhotic patients, the metabolism of lipid is changed such that glycogen stores are significantly diminished, contributing to malnutrition and biolysis.

Description:

Cirrhosis is defined anatomically as a diffuse process with fibrosis and nodule formation. It is the result of the fibrogenesis that occurs with chronic liver injury.

Lipoproteins are complexes of lipid and proteins that are essential for transport of soluble vitamins Liver cells play a serious task in the regulation of lipid metabolism. The principal location for lipoprotein and cholesterol synthesis is in the liver.

In healthy individuals, a compound equilibrium is preserved between utilization, biosynthesis, and transfer of lipid fractions.

Many diseases that affect the parenchyma can lead to changes in the structure of lipoproteins and transport throughout the blood.

Nevertheless, in cirrhotic patients, the metabolism of lipid is changed such that glycogen stores are significantly diminished, contributing to malnutrition and biolysis.

The preceding studies have reported that cirrhotic patients have abnormal metabolism of lipids, especially reduction in cholesterol level and hypobetalipoproteinemia.

These alterations develop together with the progression of liver disease and may be considered as a prognostic markers for liver decompensation.

The maneuvers concerned with the decline of lipid particles in patients with cirrhosis are compound and need multiple researches for complete understanding.

Protein microsomal triglyceride (TG) transfer protein -+ MTP], enzymatic (acylCoA:

cholesterol acyltransferase), and apoprotein (Apo AI) reduction are considered to be linked to these changes.

Owing to the wide occurrence of liver disease in Egypt, we made this study to assess lipid profile in cirrhotic patients and to evaluate its relation to the degree of cirrhosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: September 1, 2021
• Est. primary completion date: September 1, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Cirrhotic patients .

Exclusion Criteria:

• 1-Patients with diabetes mellitus,malignancy,uremia. 2-Patients with history of drugs for dyslipidemia. 3- Patients presented with hepatocellular carcinoma 4- Wilsons disease. 5-Rheumatoid arthritis. 6- Systemic lupus.

Related Conditions & MeSH terms

• Cirrhosis
• Fibrosis

Locations

Country	Name	City	State
Egypt	Sohag University	Sohag

Sponsors (1)

Lead Sponsor	Collaborator
Sohag University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measurement of the lipid profile in cirrhotic patients and compare its levels with normal persons.	Via measurement the levels of triglyceride (TG), total cholesterol,very low-density lipoprotein, low density lipoprotien (LDH), and high-density lipoprotien (HDL) in cirrhotic patients and compare with the control.	15 weeks from start point.
Secondary	Measurement the degree of liver cirrhosis severity and its relationship to lipid profile levels.	Via detecting degree of cirrhosis (according to Child score ) and its relation to the degree of lipid profile.	15 weeks from start point